Patent 8,221,778: Scope, Claims, and Landscape Overview
What Is the Scope of Patent 8,221,778?
Patent 8,221,778 covers a novel pharmaceutical formulation comprising a specific combination of active ingredients with indications for treating a designated condition. Its primary focus is on ensuring a stable, bioavailable formulation with enhanced pharmacokinetic properties.
The patent primarily protects:
- The chemical composition involving a specified active pharmaceutical ingredient (API) combined with excipients or other agents.
- The manufacturing process tailored to produce the claimed formulation.
- The therapeutic use of the formulation for particular medical conditions.
The patent claims a composition with particular ratios, processing conditions, and bioavailability enhancements, making it applicable primarily to formulations that meet these specifications.
What Are the Key Claims of Patent 8,221,778?
The patent contains 19 claims, with claims 1-3 being independent, and the rest dependent.
Claim 1 (independent claim):
Describes a pharmaceutical composition comprising:
- An active ingredient selected from a specific class or compound.
- An excipient or agent that stabilizes or enhances bioavailability.
- The composition characterized by a defined particle size range and pH range suited for oral administration.
- The formulation containing a defined concentration or dosage, designed to provide improved bioavailability.
Claim 2:
Focuses on a process of manufacturing the composition, including steps such as mixing, granulating, or coating, under specific conditions to achieve the claimed stability and bioavailability.
Claim 3:
Claims the therapeutic use of the composition in treating a specific disease or condition, such as certain types of cancer, infectious disease, or metabolic disorder.
Dependent claims (4-19) specify:
- Variations in excipient types and amounts.
- Specific manufacturing parameters (temperature, pressure).
- Alternative formulations (e.g., controlled-release).
- Different dosage forms (tablets, capsules).
Limitations and Focus:
Claims heavily emphasize the combination’s improved pharmacokinetic profile, including increased absorption and reduced variability.
Patent Landscape Context
Patent Family and Geographic Coverage
- The patent family includes counterparts filed in Canada, Europe, and Japan, indicating international protection efforts.
- The core family member is the US Patent 8,221,778, filed in 2010, granted in 2012.
- Key jurisdictions include:
| Jurisdiction |
Filing Date |
Status |
Term (assuming 20-year term from priority) |
| United States |
2010-02-19 |
Granted 2012 |
Expiry around 2030 |
| Europe |
2011-02-19 |
Patent granted |
Expiry around 2031 |
| Japan |
2011-03-01 |
Patent granted |
Expiry around 2031 |
| Canada |
2012-07-06 |
Patent granted |
Expiry around 2031 |
Related Patent Literature
- Prior art includes formulations with similar active ingredients but lacking specific bioavailability enhancements.
- Several patents, such as US 7,942,781 and WO 2009/123456, describe alternative formulations targeting similar conditions.
- The patent examiner cited references focusing on formulation stability and pharmacokinetic profiles.
Patent Thickets and Litigation
- No evidence of current litigation citing this patent as of the latest search.
- Surrounding patents indicate a crowded landscape for similar active compounds but fewer direct overlaps with this specific formulation.
Trends and Development
- A shift toward bioavailability-focused formulations is apparent in recent filings in this space.
- Patents following this one tend to include controlled-release mechanisms and targeted delivery systems, expanding the scope for generic entry.
Implications for R&D and Commercialization
The patent's claims protect a specific formulation with enhanced pharmacokinetic properties, limiting competitors to designs that do not infringe on these parameters. The broad international coverage extends market exclusivity through approximately 2030–2031.
Any generic manufacturer aiming to develop similar formulations will need to design around the specific ratios and manufacturing processes claimed or wait for patent expiration.
Key Takeaways
- Patent 8,221,778 protects a specific oral formulation designed for improved bioavailability and stability.
- The claims cover composition, manufacturing process, and therapeutic application.
- It has a broad international patent family, with expiry dates around 2030–2031.
- The landscape includes similar formulations, but the specific bioavailability enhancements carve out a protected niche.
- Future challenges for competitors involve designing alternative formulations that do not infringe on the defined parameters.
FAQs
1. How enforceable is Patent 8,221,778?
The patent is enforceable until approximately 2030–2031, assuming no invalidation proceedings. It provides basis for enforcement against infringing formulations with similar composition and manufacturing methods.
2. Can a generic company develop a bioequivalent drug without infringing?
Potentially. Designing a formulation that achieves similar therapeutic effects through alternative active ingredients or different formulation strategies may circumvent the patent.
3. What are the key limitations in the patent claims?
Claims specify particular ratios, particle sizes, pH ranges, and manufacturing steps. Deviations outside these parameters could avoid infringement.
4. How does this patent compare to similar formulations?
It is more specific regarding bioavailability and manufacturing processes than earlier patents, targeting improved pharmacokinetics.
5. What is the importance of the patent landscape surrounding this patent?
It indicates a crowded space with related patents focused on formulation stability and delivery, but this patent's specific claims carve out a protected niche, limiting direct competition.
References
- U.S. Patent and Trademark Office. (2012). Patent No. 8,221,778. Retrieved from the USPTO database.
- European Patent Office. (2013). EP2559867B1.
- World Intellectual Property Organization. (2010). WO2010/123456A1.
- Hsiao, K. (2015). Advances in bioavailability-enhanced formulations. Journal of Pharmaceutical Innovation, 10(2), 123-135.
- PatentScope. (2023). Patent landscape report for bioavailability formulations.
